查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
南美洲和中美洲生物製藥市場預測至 2028 年 - 區域分析 - 按產品類型和應用
市場調查報告書
商品編碼
1360071

南美洲和中美洲生物製藥市場預測至 2028 年 - 區域分析 - 按產品類型和應用

South & Central America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type and Application
出版日期: | 出版商: The Insight Partners | 英文 220 Pages | 訂單完成後即時交付

價格

2022年，南美洲和中美洲生物製藥市場估值為178.5億美元，預計到2028年將達到349.7億美元。預計2022年至2028年年複合成長率為11.9%。

生物製藥合約製造推動南美洲和中美洲生物製藥市場

合約製造組織 (CMO) 為製藥公司帶來了許多好處。將任務外包給首席行銷長有助於他們減少營運和維護製造設施所需的投資，從而有助於改善淨現金流。外包成本更低，並且提高了製造流程的效率。此外，它還允許生物製藥公司將資源重新分配到其他重要領域。許多生物製藥公司正在重新關注其核心能力，例如研發，導致內部製造能力的剝離，從而導致製造對 CMO 的依賴增加。 CMO 為製藥公司提供額外的產能和額外的場地，透過多地點供應策略和備用能力來減輕供應短缺的風險。例如，2022年3月，BioNTech SE 宣布與Regeneron 合作，推進FixVac 候選BNT116 與Libtayo (cemiplimab) 的組合，Libtayo (cemiplimab) 是一種用於治療晚期非小細胞肺癌(NSCLC) 的PD-1 抑制劑。該合作協議允許兩家公司聯合進行臨床試驗，以評估不同晚期非小細胞肺癌患者的聯合療法。因此，生物製藥合約製造的日益普及可能會在未來幾年促進南美洲和中美洲生物製藥市場的成長。

南美洲和中美洲生物製藥市場概況

南美洲和中美洲生物製藥市場分為巴西、阿根廷以及南美洲和中美洲其他地區。數位放射線攝影在南美洲和中美洲的成像中心變得越來越普遍。癌症的高負擔、生物製藥技術的不斷創新、患癌症風險較高的老年人口的增加以及對各種即將上市的新藥物的研究是促進南美洲和中美洲生物製藥市場成長的因素。生物製藥產品是醫學史上最重要的創新之一。然而，這些突破性療法由於發現和開發需要大量投資而極其昂貴，因此需要更便宜的替代品。南美洲和中美洲為生物藥品，特別是生物相似藥提供了巨大的機會。在南美洲和中美洲，生物相似藥的知識和開發水準很高；因此，本地和外國製藥公司對進入該市場進行本地和國際研究、生產和商業化有很大興趣。生物製品市場將在預測期內快速成長，這主要是由於新分子的發現。製造生物製品所需的先進技術和資源為小型生物技術公司創造了很高的進入障礙。這解釋了為什麼大型跨國公司主導了該地區的整個生物製品市場。這些公司在研發方面投入巨資，透過不斷提供新的創新產品，在生物相似藥市場中保持領先地位。南美洲和中美洲生物相似藥市場參與者面臨的主要挑戰與研發成本高、證明產品功效和安全性所需的臨床試驗以及維持低階價格的需要有關。在南美洲和中美洲，市面上出現的第一個生物相似藥產品是胰島素：粒細胞集落刺激因子（G-CSF）、促紅血球生成素和人類生長激素。後來干擾素來到了這個地區，最後是單株抗體。此外，利妥昔單抗、依那塞普和雷妥尤單抗等產品進入南美洲和中美洲市場將擴大生物相似藥的市場。由於地理擴張和經濟成長，多家全球製藥公司選擇了巴西市場。由於他們在生物相似藥市場的技能，他們將幫助當地公司更快地擴大市場，從而推動該地區南美洲和中美洲的生物製藥市場。

南美洲和中美洲生物製藥市場收入及 2028 年預測（十億美元）

南美洲和中美洲生物製藥市場細分

南美洲和中美洲生物製藥市場按產品類型、應用和國家細分。

根據產品類型，南美洲和中美洲生物製藥市場分為單株抗體、重組疫苗、常規疫苗、重組生長因子、純化蛋白、重組蛋白、重組激素、重組酶、細胞和基因療法、細胞激素/干擾素/白細胞介素， 和別的。 2022年，單株抗體領域在南美洲和中美洲生物製藥市場中佔據最大佔有率。

重組疫苗細分為癌症疫苗、瘧疾疫苗、伊波拉疫苗、B型肝炎疫苗、破傷風疫苗、白喉疫苗、霍亂疫苗等。傳統疫苗細分為小兒麻痺疫苗、痘疫苗等。重組生長因子片段進一步細分為紅血球生成素和粒細胞集落刺激因子。純化的蛋白質片段進一步細分為白血病抑制因子（LIF）、P53蛋白、P38蛋白等。重組蛋白片段進一步分為血清白蛋白、澱粉樣蛋白、防禦素和轉鐵蛋白。重組激素細分為重組人生長激素、重組胰島素和其他重組激素。重組酶片段進一步分為腸激酶、環化酶、半胱天冬酶和組織蛋白酶。細胞和基因治療領域進一步細分為同種異體產品、自體產品和非細胞產品。

根據應用，南美洲和中美洲生物製藥市場分為腫瘤學、發炎和傳染病、自體免疫疾病、代謝失調、荷爾蒙失調和生長障礙、心血管疾病、神經系統疾病等。 2022年，腫瘤學領域在南美洲和中美洲生物製藥市場中佔據最大佔有率。

根據國家/地區，南美洲和中美洲生物製藥市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022年，巴西在南美洲和中美洲生物製藥市場中佔據最大佔有率。

艾伯維公司、AGC Biologics AS、安進公司、勃林格殷格翰國際有限公司、百時美施貴寶公司、禮來公司、強生公司、龍沙集團和賽默飛世爾科技公司都是在南部和中部地區營運的領先公司美國生物製藥市場。

目錄

第 1 章：簡介

  • 研究範圍
  • Insight Partners 研究報告指南
  • 市場區隔
    • 南美洲和中美洲生物製藥市場 - 按產品類型
    • 南美洲和中美洲生物製藥市場 - 按應用
    • 南美洲和中美洲生物製藥市場 - 按國家/地區

第 2 章：南美洲和中美洲生物製藥市場 - 要點

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：南美洲和中美洲生物製藥市場 - 市場格局

  • 概述
  • 南美洲和中美洲 PEST 分析
  • 專家意見

第 5 章：南美洲和中美洲生物製藥市場 - 主要市場動態

  • 市場促進因素
    • 在癌症治療的應用不斷增加
    • 治療罕見疾病的潛力
  • 市場限制
    • 製造基礎設施成本高昂
  • 市場機會
    • 加速臨床試驗
  • 未來的趨勢
    • 生物製藥合約製造
  • 影響分析

第 6 章：生物製藥市場 - 南美洲和中美洲分析

  • 南美洲和中美洲生物製藥市場收入預測與分析

第 7 章：南美洲和中美洲生物製藥市場 - 2028 年收入和預測 - 按產品類型

  • 概述
  • 2021 年和 2028 年按產品類型分類的生物製藥市場收入佔有率 (%)
  • 單株抗體
  • 重組疫苗
  • 常規疫苗
  • 重組生長因子
  • 純化蛋白質
  • 重組蛋白
  • 重組激素
  • 重組酵素
  • 細胞和基因療法
  • 細胞激素/干擾素/白血球介素
  • 其他（基於 mRNA 的療法等）

第 8 章：2028 年南美洲和中美洲生物製藥市場分析和預測 -按應用

  • 概述
  • 南美洲和中美洲生物製藥市場，按應用分類 2021 年和 2028 年 (%)
  • 腫瘤學
  • 發炎和傳染病
  • 自體免疫疾病
  • 代謝紊亂
  • 荷爾蒙失調與生長障礙
  • 心血管疾病
  • 神經系統疾病
  • 其他治療應用

第 9 章：南美洲和中美洲生物製藥市場 - 2028 年收入和預測 - 國家分析

    • 南美洲和中美洲
      • 巴西
      • 阿根廷
      • 南美洲和中美洲其他地區

第 10 章：南美洲和中美洲生物製藥市場 - 產業格局

  • 概述
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 11 章：公司簡介

  • Amgen Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Thermo Fisher Scientific Inc
  • AGC Biologics AS
  • Lonza Group AG

第 12 章：附錄

  • 關於 Insight Partners
  • 專業術語
Product Code: BMIRE00028654

The South & Central America biopharmaceuticals market was valued at US$ 17.85 billion in 2022 and is projected to reach US$ 34.97 billion by 2028. It is estimated to grow at a CAGR of 11.9% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drives South & Central America Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceutical companies to redirect resources to other important areas. Many biopharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increased dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron to advance the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the South & Central America biopharmaceuticals market in the coming years.

South & Central America Biopharmaceuticals Market Overview

The South & Central America Biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Digital radiography is becoming more prevalent in imaging centers across South & Central America. The high burden of cancer, ongoing innovations in biopharmaceuticals technologies, increase in the geriatric population that is at a greater risk of cancer, and research studies on various new upcoming medicines are among the factors contributing to the growth of biopharmaceuticals market in South & Central America. Biopharmaceuticals products are among the most important innovations in medical history. However, these breakthrough therapies, which are extremely expensive due to the large investments required for their discovery and development, call for cheaper alternatives. South & Central America provides a great opportunity for biologic medicines, particularly biosimilars. In South & Central America, there is a high level of knowledge and development of biosimilars; hence, there is a great interest in local and foreign pharmaceutical companies to enter the market to research, manufacture, and commercialize locally and internationally. The biologics market is set to grow rapidly over the forecast period, mainly due to the discovery of new molecules. The advanced technology and resources required to manufacture biologics create high barriers to entry for small biotech companies. This explains why large multinational companies dominate the entire biologics market in the region. These companies invest heavily in R&D to stay ahead in the biosimilar market by constantly offering new innovative products. The main challenges faced by participants in the South & Central America biosimilar market are related to the high cost of research and development, the clinical trials required to prove product efficacy and safety, and the need to maintain low-end prices. In South & Central America, the first biosimilar product to appear on the market was insulin: granulocyte colony-stimulating factor (G-CSF), erythropoietin, and human growth hormone. Interferon later came to the region, and finally, monoclonal antibodies. In addition, the market entry of products such as rituximab, etanercep, and racotunumab in South & Central America would expand the market for biosimilars. Several global pharmaceutical companies have chosen the Brazil market due to their geographic expansion and growing economy. Because of their skills in the biosimilars market, they will help expand the market faster with only local companies, thereby boosting the South & Central America biopharmaceuticals market in the region.

South & Central America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America biopharmaceuticals market Segmentation

The South & Central America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the South & Central America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the South & Central America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the South & Central America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the South & Central America biopharmaceuticals market.

Based on country, the South & Central America biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil held the largest share of the South & Central America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the South & Central America biopharmaceuticals market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America biopharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
  • develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 South & Central America Biopharmaceuticals Market - by Product Type
    • 1.3.2 South & Central America Biopharmaceuticals Market - by Application
    • 1.3.3 South & Central America Biopharmaceuticals Market - by Country

2. South & Central America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Biopharmaceuticals Market - Market Landscape

  • 4.1 Overview
  • 4.2 South & Central America PEST Analysis
  • 4.3 Expert's Opinion

5. South & Central America Biopharmaceuticals Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Application in Cancer Therapeutics
    • 5.1.2 Potential to Treat Rare Diseases
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Manufacturing Infrastructure
  • 5.3 Market Opportunities
    • 5.3.1 Accelerated Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Contract Manufacturing of Biopharmaceuticals
  • 5.5 Impact Analysis

6. Biopharmaceuticals Market - South & Central America Analysis

  • 6.1 South & Central America Biopharmaceuticals Market Revenue Forecast and Analysis

7. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • 7.3 Monoclonal Antibodies
    • 7.3.1 Overview
    • 7.3.2 Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Recombinant Vaccines
    • 7.4.1 Overview
    • 7.4.2 Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Cancer Vaccine
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Malaria Vaccine
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Ebola Vaccine
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Hepatitis-B Vaccine
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.5 Tetanus Vaccine
        • 7.4.2.5.1 Overview
        • 7.4.2.5.2 Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.6 Diphtheria Vaccine
        • 7.4.2.6.1 Overview
        • 7.4.2.6.2 Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.7 Cholera Vaccine
        • 7.4.2.7.1 Overview
        • 7.4.2.7.2 Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.8 Others
        • 7.4.2.8.1 Overview
        • 7.4.2.8.2 Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Conventional Vaccines
    • 7.5.1 Overview
    • 7.5.2 Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Polio Vaccine
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Pox Vaccine
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Other Conventional Vaccine
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Recombinant Growth Factors
    • 7.6.1 Overview
    • 7.6.2 Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 Erythropoietin
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Granulocyte Colony Stimulating Factor
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Purified Proteins
    • 7.7.1 Overview
    • 7.7.2 Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 P53 Protein
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.3 P38 Protein
        • 7.7.2.3.1 Overview
        • 7.7.2.3.2 P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.4 Other Purified Proteins
        • 7.7.2.4.1 Overview
        • 7.7.2.4.2 Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Recombinant Proteins
    • 7.8.1 Overview
    • 7.8.2 Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.1 Serum Albumin
        • 7.8.2.1.1 Overview
        • 7.8.2.1.2 Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.2 Amyloid Protein
        • 7.8.2.2.1 Overview
        • 7.8.2.2.2 Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.3 Defensin
        • 7.8.2.3.1 Overview
        • 7.8.2.3.2 Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.4 Transferrin
        • 7.8.2.4.1 Overview
        • 7.8.2.4.2 Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Recombinant Hormones
    • 7.9.1 Overview
    • 7.9.2 Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.1 Recombinant Human Growth Hormones
        • 7.9.2.1.1 Overview
        • 7.9.2.1.2 Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.2 Recombinant Insulin
        • 7.9.2.2.1 Overview
        • 7.9.2.2.2 Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.3 Other Recombinant Hormones
        • 7.9.2.3.1 Overview
        • 7.9.2.3.2 Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Recombinant Enzymes
    • 7.10.1 Overview
    • 7.10.2 Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.1 Enterokinase
        • 7.10.2.1.1 Overview
        • 7.10.2.1.2 Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.2 Cyclase
        • 7.10.2.2.1 Overview
        • 7.10.2.2.2 Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.3 Caspase
        • 7.10.2.3.1 Overview
        • 7.10.2.3.2 Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.4 Cathepsin
        • 7.10.2.4.1 Overview
        • 7.10.2.4.2 Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.11 Cell and Gene Therapies
    • 7.11.1 Overview
    • 7.11.2 Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.1 Allogenic Products
        • 7.11.2.1.1 Overview
        • 7.11.2.1.2 Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.2 Autologous Products
        • 7.11.2.2.1 Overview
        • 7.11.2.2.2 Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.3 Acellular Products
        • 7.11.2.3.1 Overview
        • 7.11.2.3.2 Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.12 Cytokines/Interferon/Interleukins
    • 7.12.1 Overview
    • 7.12.2 Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.13 Others (mRNA Based Therapeutics, etc.)
    • 7.13.1 Overview
    • 7.13.2 Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

  • 8.1 Overview
  • 8.2 South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Inflammatory and Infectious Diseases
    • 8.4.1 Overview
    • 8.4.2 Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Metabolic Disorders
    • 8.6.1 Overview
    • 8.6.2 Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Hormonal Disorders and Growth Failure
    • 8.7.1 Overview
    • 8.7.2 Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Neurological Diseases
    • 8.9.1 Overview
    • 8.9.2 Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Other Therapeutic Applications
    • 8.10.1 Overview
    • 8.10.2 Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.1 South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
      • 9.1.1.1 Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.1.1 Brazil: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.1.1.1 Brazil: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.2 Brazil: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.3 Brazil: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.1.1.4 Brazil: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.5 Brazil: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.6 Brazil: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.1.1.7 Brazil: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.1.1.8 Brazil: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.1.2 Brazil: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.2 Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.2.1 Argentina: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.2.1.1 Argentina: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.2 Argentina: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.3 Argentina: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.2.1.4 Argentina: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.5 Argentina: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.6 Argentina: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.2.1.7 Argentina: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.2.1.8 Argentina: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.2.2 Argentina: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.3 Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.3.1 Rest of South & Central America: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.3.1.1 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.2 Rest of South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.3 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.3.1.4 Rest of South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.5 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.6 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.3.1.7 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.3.1.8 Rest of South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.3.2 Rest of South & Central America: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. South & Central America Biopharmaceuticals Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Amgen Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Eli Lilly and Co
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Bristol-Myers Squibb Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Johnson & Johnson
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Boehringer Ingelheim International GmbH
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 AGC Biologics AS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Lonza Group AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. Brazil Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Brazil Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Brazil Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Brazil Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Brazil Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Brazil Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Brazil Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Brazil Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Brazil Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Brazil Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Argentina Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Argentina Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Argentina Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Argentina Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Argentina Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Argentina Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Argentina Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Argentina Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Argentina Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Argentina Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Rest of South & Central America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Rest of South & Central America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Rest of South & Central America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Rest of South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Rest of South & Central America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
  • Table 33. Recent Inorganic Growth Strategies in the South & Central America biopharmaceuticals market
  • Table 34. Glossary of Terms

List Of Figures

  • Figure 1. South & Central America Biopharmaceuticals Market Segmentation
  • Figure 2. South & Central America Biopharmaceuticals Market, by Country
  • Figure 3. South & Central America Biopharmaceuticals Market Overview
  • Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in South & Central America Biopharmaceuticals Market
  • Figure 5. Brazil Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. South & Central America: PEST Analysis
  • Figure 7. Experts\' Opinion
  • Figure 8. South & Central America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
  • Figure 9. South & Central America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 42. Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 51. Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • Figure 54. Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 59. Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 61. Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. South & Central America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 63. South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  • Figure 64. Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 65. Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 66. Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)